Chris Somogyi is an experienced commercialization venture capitalist, entrepreneur and executive across a wide variety of subject areas, all technical in nature. Chris’s well-rounded background creates a unique vantage point from which he understands the challenges and opportunities facing the technology commercialization pathway from all angles.
Chris’ venture capital experience spans three funds: a fund focused on commercializing SRI International lab’s innovations; a $30 million Japanese biotechnology fund investing globally in devices, pharma and biotech, with IPO exits including LipoScience (LPDX), Acadia Pharmaceuticals (ACAD), Methylgene (MYLGF) and Tranzyme (TZYM); and a $6 billion family fund emphasizing intellectual property creation and commercialization.
Chris is also an experienced angel investor, having made some 15 private angel investments, and having served on the executive committee for Seattle’s Alliance of Angels group.
As a venture-backed entrepreneur, Chris received numerous grants and patents, and negotiated venture investments from both U.S. and foreign investment groups. Chris launched eight companies over the past 25 years, and negotiated and managed several corporate partnership deals and technology licensing agreements.
Chris is a champion of technical innovation and driver of new business formation at the cross section of technology commercialization and compelling market conditions. Chris served as the lead advocate for innovation across New Zealand industry, and managed the country’s NZ$500 million innovation grant program to stimulate rapid innovation commercialization in the country.
Chris is a former guest lecturer on entrepreneurship at the University of Washington Foster School of Business and the University of Auckland Business School. Chris continues to enjoy advising, coaching and facilitating network connections for entrepreneurs as they advance their efforts.